PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.
Never miss a new study
Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear
Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare overgrowth disorder: drug targets root cause
Disease control OngoingThis study tests a drug called alpelisib in children and adults with PROS, a rare condition that causes abnormal overgrowth of body tissues. The goal is to see if the drug can shrink these growths by at least 20%. Participants are randomly assigned to receive either alpelisib or …
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Rare overgrowth disorder drug tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug alpelisib in children and adults with PIK3CA-related overgrowth spectrum (PROS), a rare condition that causes abnormal growth. All 41 participants had already taken alpelisib in a previous study. Researchers w…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:38 UTC